NASDAQ:VBIV - VBI Vaccines Stock Price, News, & Analysis Sign in or create an account to add this stock to your watchlist. Get Started $1.86 -0.11 (-5.58 %) (As of 03/26/2019 03:54 AM ET)Previous Close$1.97Today's Range$1.84 - $1.9652-Week Range$1.14 - $3.95Volume247,783 shsAverage Volume383,432 shsMarket Capitalization$181.65 millionP/E Ratio-1.92Dividend YieldN/ABeta1.27 ProfileDiscussionAnalyst RatingsChartEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email VBI Vaccines Inc., a biopharmaceutical company, develops and sells vaccines to address unmet needs in infectious disease and immuno-oncology in Israel and internationally. The company offers Sci-B-Vac, a third-generation hepatitis B vaccine for adults, children, and newborns; and eVLP, a vaccine platform for the design of enveloped virus-like particle vaccines that closely mimic the target virus. It is also developing congenital cytomegalovirus vaccine candidate for infectious disease; and therapeutic glioblastoma multiforme vaccine candidate for immuno-oncology. The company was formerly known as SciVac Therapeutics Inc. and changed its name to VBI Vaccines Inc. in May 2016. The company is headquartered in Cambridge, Massachusetts. VBI Vaccines Inc. is a subsidiary of FDS Pharma ASS. Receive VBIV News and Ratings via Email Sign-up to receive the latest news and ratings for VBIV and its competitors with MarketBeat's FREE daily newsletter. Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:VBIV Previous Symbol CUSIPN/A CIK764195 Webwww.vbivaccines.com Phone617-830-3031Debt Debt-to-Equity Ratio0.13 Current Ratio2.64 Quick Ratio2.60Price-To-Earnings Trailing P/E Ratio-1.92 Forward P/E Ratio-3.44 P/E GrowthN/A Sales & Book Value Annual Sales$3.36 million Price / Sales54.06 Cash FlowN/A Price / Cash FlowN/A Book Value$1.08 per share Price / Book1.72Profitability EPS (Most Recent Fiscal Year)($0.97) Net Income$-63,600,000.00 Net Margins-1,895.74% Return on Equity-68.48% Return on Assets-50.79%Miscellaneous EmployeesN/A Outstanding Shares97,662,000Market Cap$181.65 million Next Earnings Date5/7/2019 (Estimated) OptionableOptionable VBI Vaccines (NASDAQ:VBIV) Frequently Asked Questions What is VBI Vaccines' stock symbol? VBI Vaccines trades on the NASDAQ under the ticker symbol "VBIV." How were VBI Vaccines' earnings last quarter? VBI Vaccines Inc (NASDAQ:VBIV) issued its quarterly earnings data on Monday, February, 25th. The biopharmaceutical company reported ($0.28) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.19) by $0.09. VBI Vaccines had a negative net margin of 1,895.74% and a negative return on equity of 68.48%. View VBI Vaccines' Earnings History. When is VBI Vaccines' next earnings date? VBI Vaccines is scheduled to release their next quarterly earnings announcement on Tuesday, May 7th 2019. View Earnings Estimates for VBI Vaccines. What price target have analysts set for VBIV? 2 equities research analysts have issued 12-month price targets for VBI Vaccines' stock. Their forecasts range from $9.00 to $12.00. On average, they expect VBI Vaccines' share price to reach $10.50 in the next year. This suggests a possible upside of 464.5% from the stock's current price. View Analyst Price Targets for VBI Vaccines. What is the consensus analysts' recommendation for VBI Vaccines? 2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for VBI Vaccines in the last year. There are currently 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for VBI Vaccines. Has VBI Vaccines been receiving favorable news coverage? News coverage about VBIV stock has been trending neutral this week, according to InfoTrie. The research firm identifies negative and positive news coverage by reviewing more than six thousand blog and news sources in real time. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. VBI Vaccines earned a news impact score of 0.2 on InfoTrie's scale. They also assigned press coverage about the biopharmaceutical company a news buzz of 8.0 out of 10, meaning that recent news coverage is very likely to have an impact on the company's share price in the near future. Are investors shorting VBI Vaccines? VBI Vaccines saw a decline in short interest during the month of February. As of February 15th, there was short interest totalling 981,006 shares, a decline of 43.6% from the January 31st total of 1,739,334 shares. Based on an average daily trading volume, of 296,416 shares, the short-interest ratio is currently 3.3 days. Approximately 1.3% of the company's shares are short sold. View VBI Vaccines' Current Options Chain. Who are some of VBI Vaccines' key competitors? Some companies that are related to VBI Vaccines include Rocket Pharmaceuticals (RCKT), Cara Therapeutics (CARA), CymaBay Therapeutics (CBAY), Revance Therapeutics (RVNC), Vectura Group (VEGPF), Intra-Cellular Therapies (ITCI), ZIOPHARM Oncology (ZIOP), Lexicon Pharmaceuticals (LXRX), Eagle Pharmaceuticals (EGRX), Evolus (EOLS), DiaMedica Therapeutics (DMCAF), Synthorx (THOR), Magenta Therapeutics (MGTA), TG Therapeutics (TGTX) and Viking Therapeutics (VKTX). What other stocks do shareholders of VBI Vaccines own? Based on aggregate information from My MarketBeat watchlists, some companies that other VBI Vaccines investors own include Synergy Pharmaceuticals (SGYP), Progenics Pharmaceuticals (PGNX), Rigel Pharmaceuticals (RIGL), Novavax (NVAX), Fate Therapeutics (FATE), Catalyst Pharmaceuticals (CPRX), Sangamo Therapeutics (SGMO), Eyepoint Pharmaceuticals (EYPT), Melinta Therapeutics (MLNT) and Verastem (VSTM). Who are VBI Vaccines' key executives? VBI Vaccines' management team includes the folowing people: Mr. Jeff R. Baxter, CEO, Pres & Director (Age 58)Dr. David Evander Anderson, Chief Scientific Officer (Age 49)Dr. Francisco Diaz-Mitoma, Chief Medical Officer (Age 64)Mr. Christopher McNulty, CFO & Head of Bus. Devel. (Age 42)Ms. Athena Kartsaklis, Sr. VP of Fin., Chief Compliance Officer & Principal Financial Officer (Age 54) Who are VBI Vaccines' major shareholders? VBI Vaccines' stock is owned by a variety of of retail and institutional investors. Top institutional shareholders include Perceptive Advisors LLC (26.27%), Menora Mivtachim Holdings LTD. (5.77%), General American Investors Co. Inc. (1.94%), Cambridge Investment Research Advisors Inc. (1.48%), Millennium Management LLC (0.83%) and Fosun International Ltd (0.71%). Company insiders that own VBI Vaccines stock include Francisco Diaz-Mitoma, Jeff Baxter, Life Sciences Maste Perceptive, Nell Beattie, Opko Health, Inc, Perceptive Advisors Llc, Steven Gillis and Tomer Kariv. View Institutional Ownership Trends for VBI Vaccines. Which major investors are selling VBI Vaccines stock? VBIV stock was sold by a variety of institutional investors in the last quarter, including Cambridge Investment Research Advisors Inc.. View Insider Buying and Selling for VBI Vaccines. Which major investors are buying VBI Vaccines stock? VBIV stock was bought by a variety of institutional investors in the last quarter, including Perceptive Advisors LLC, Menora Mivtachim Holdings LTD., General American Investors Co. Inc., Fosun International Ltd, Millennium Management LLC, CVI Holdings LLC, Geode Capital Management LLC and Geode Capital Management LLC. Company insiders that have bought VBI Vaccines stock in the last two years include Francisco Diaz-Mitoma, Jeff Baxter, Life Sciences Maste Perceptive, Nell Beattie, Opko Health, Inc, Perceptive Advisors Llc, Steven Gillis and Tomer Kariv. View Insider Buying and Selling for VBI Vaccines. How do I buy shares of VBI Vaccines? Shares of VBIV can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab. What is VBI Vaccines' stock price today? One share of VBIV stock can currently be purchased for approximately $1.86. How big of a company is VBI Vaccines? VBI Vaccines has a market capitalization of $181.65 million and generates $3.36 million in revenue each year. The biopharmaceutical company earns $-63,600,000.00 in net income (profit) each year or ($0.97) on an earnings per share basis. What is VBI Vaccines' official website? The official website for VBI Vaccines is http://www.vbivaccines.com. How can I contact VBI Vaccines? VBI Vaccines' mailing address is 222 Third Street Suite 2241, Cambridge MA, 02142. The biopharmaceutical company can be reached via phone at 617-830-3031 or via email at [email protected] MarketBeat Community Rating for VBI Vaccines (NASDAQ VBIV)Community Ranking: 2.8 out of 5 ( )Outperform Votes: 233 (Vote Outperform)Underperform Votes: 179 (Vote Underperform)Total Votes: 412MarketBeat's community ratings are surveys of what our community members think about VBI Vaccines and other stocks. Vote "Outperform" if you believe VBIV will outperform the S&P 500 over the long term. Vote "Underperform" if you believe VBIV will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 3/26/2019 by MarketBeat.com StaffFeatured Article: Is it better to buy a fund with a higher or lower NAV?